A major five-year strategic drug discovery alliance, to discover and develop new cancer drugs, has been formed by Astex Pharmaceuticals, Cancer Research Technology Limited and Newcastle University.

CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a ...

ASTX528 is a novel small molecule CBP/p300 HAT domain inhibitor with potent in vivo activity and a favourable safety profile in preclinical species that was discovered by Astex using its proprietary ...

The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic ...

Astex Pharmaceuticals has initiated phase 2, open-label, single-arm, clinical trials evaluating SGI-110 in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment ...

PLEASANTON, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., based in Tokyo, Japan, announces that the US Food & Drug Administration ...

PLEASANTON, Calif. & HOUSTON--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, and The University of Texas MD Anderson ...

In the latest buyout of what’s been a busy M&A week, Japanese drug maker Otsuka inked an $886 million pact on Thursday to snag U.S. cancer treatment maker Astex (NASDAQ:ASTX). The deal will allow ...

For nearly two decades, blood cancer patients have depended upon time-consuming infusions of the chemotherapy decitabine. Now, with an FDA approval for Astex Pharmaceuticals' oral version, they have ...

The companies plan to combine their preclinical candidates to develop small-molecule inhibitors against multiple drug targets. Merck announced on Jan. 6, 2020 that it is entering into a research ...

LONDON (Reuters) - Astex Therapeutics has signed a cancer drug research deal with Johnson & Johnson potentially worth more than $500 million (253 million pounds) in milestone payments, it said on ...